International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

COVID-19 Commentaries

Read the views of IPC’s global experts regarding COVID-19 and psoriasis management.

Errol Prens, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

MAY 17, 2022


Sex differences in immune responses that underlie COVID-19 disease outcomes. Takahashi T, Ellingson MK, Wong P. Nature. 2020 Dec; 588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26. PMID: 32846427; PMCID: PMC7725931.

Arnon Cohen Headshot

Arnon Cohen, MD, MPH, PhD
Clalit Health Services
Tel Aviv, Israel

JANUARY 26, 2022


Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Satveer K Mahil, Katie Bechman, Antony Raharja, et al. Lancet Rheumatol. 2022; Vol 4:e42–52.

Luigi Naldi, MD
Centro Studi GISED
Bergamo, Italy

July 7, 2021


Coronavirus Disease 2019 (COVID‐19)‐Associated Hospitalization and Mortality in Patients with Psoriasis: A Population‐Based Study. Kridin K, Schonmann Y, Tzur Bitan D, et al. American Journal of Clinical Dermatology.

Lars Iversen, MD, DMSc
Aarhus University Hospital
Aarhus, Denmark
IPC Board Member

MAY 25, 2021


Psoriasis. Griffiths C, Armstrong A, Gudjonsson J, Barker J. Lancet. vol. 397. no. 10281. 2021 Apr; 397: 1301–15. doi: 10.1016/s0140-6736(20)32549-6.


Francesca Capon, MD
Guy’s Hospital
London, England, United Kingdom

FEBRUARY 8, 2021


Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Patrick M,  Zhang H,  Wasikowski R, et al. J Allergy Clin Immunol. 2021 Jan 21 doi: 10.1016/j.jaci.2021.01.006 [Epub ahead of print]

Johann Gudjonsson Headshot

Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member

FEBRUARY 2, 2021


Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion. Simon D, Tascilar K, Krönke G, et al. Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6. PMID: 32709909; PMCID: PMC7382482.

Hervé Bachelez Headshot
Hervé Bachelez, MD, PhD
Department of Dermatology, Hôpital Saint-Louis, Imagine Institute for Human Genetic Diseases, University of Paris
Paris, France
IPC Vice President/President Elect
JANURARY 6, 2021


COVID-19 Task Force Guidance Statements.  The National Psoriasis Foundation. 2020 December.

Jörg Prinz, MD
Ludwig Maximilians University
Munich, Germany

OCTOBER 23, 2020


Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study. Mahil S, Dand N, Mason KJ, et al. Allergy Clin Immunol. 2020 Oct 16; S0091-6749(20)31413-5. doi: 10.1016/j.jaci.2020.10.007. [Epub ahead of print]

Alan Menter, MD
Texas Dermatology Associates
Dallas, Texas, United States
Honorary Founder

Ulrich Mrowietz, MD
University Medical Center Schleswig-Holstein
Kiel, Germany

OCTOBER 6, 2020


National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Gelfand J, Armstrong A, Bell S, et al. (2020). Journal Of The American Academy Of Dermatology. doi: 10.1016/j.jaad.2020.09.001

Marcus Schmitt-Egenolf

Marcus Schmitt-Egenolf, MD, PhD
Umea University
Umea, Sweden

AUGUST 20, 2020


Tiago Torres, MD, PhD
Abel Salazar Institute of Biomedical Sciences,
Porto, Portugal


AUGUST 13, 2020


OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Williamson EJ, Walker AJ, Bhaskaran K, et al. Nature. 2020 Jul 8. doi: 10.1038/s41586-020-2521-4.

Jo Lambert, MD, PhD
Ghent University Hospital
Ghent, Belgium

JULY 22, 2020


Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. JEADV, 2020, 34: 1196-1201.

April Armstrong, MD, MPH
Keck School of Medicine, USC
Studio City, California, United States

JULY 22, 2020


Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C. Dermatol Ther. 2020;e13495. doi:10.1111/dth.13695.

Luigi Naldi, MD
Centro Studi GISED
Bergamo, Italy

May 28, 2020


The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Wan MT, Shin DB, Winthrop KL, Gelfand JM. Journal of the American Academy of Dermatology (2020), doi:

Luis Puig is Director of the Department of Dermatology.

Lluís Puig, MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
IPC Board Member


MAY 18, 2020


Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Galván Casas C,  Català A,  Carretero Hernández G, et al. BJD. First published:29 April 2020.

Ulrich Mrowietz, MD
University Medical Center Schleswig-Holstein
Kiel, Germany

MAY 14, 2020


COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett G, Sticherling M, Neurath MF. Nat Rev Immunol. 2020;20(5):271‐272. doi:10.1038/s41577-020-0312-7

Mark Lebwohl, MD
Mt Sinai
New York, New York, United States

MAY 12, 2020


Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. A. Chen, R. Castillo, S. Adhikari, D. Hudesma.  Letter to the editor. NEJM. April 29, 2020. DOI: 10.1056/NEJMc2009567

Professor Peter van de Kerkhof served as head of the department Dermatology at the Radboud University Nijmegen Medical Centre

Peter van de Kerkhof, MD, PhD, Chief Medical Officer
International Psoriasis Council
Amsterdam, Netherlands

MAY 1, 2020


Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.  Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: j.jaad.2020.04.085.

Disclaimer: Views expressed in this commentary are those of the authors and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.

Support Our Work

Subscribe to the IPC Newsletter

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.